Cytosolic Beta-Glucosidase
EmergingGBA3/cytosolic beta-glucosidase deficiency is a benign polymorphism, distinct from the disease-associated lysosomal GBA enzyme.
This enzyme is genetically distinct from a similarly-named enzyme involved in a well-known disease (Gaucher disease). Missing this particular enzyme doesn't seem to cause any health problems, making it more of a genetic curiosity than something doctors test for clinically.
Cytosolic beta-glucosidase, encoded by the GBA3 gene, is an enzyme involved in breaking down certain glycoside compounds; it's distinct from the lysosomal GBA enzyme implicated in Gaucher disease and Parkinson's disease risk.
GBA3 deficiency is generally considered a benign genetic polymorphism without clear disease association, in contrast to its more clinically significant lysosomal cousin GBA.
GBA3 status can be determined via genetic testing, though this is done primarily in research or pharmacogenomic contexts rather than for any clinical diagnostic purpose.
There is no treatment indication associated with GBA3 status, since deficiency doesn't cause recognized disease; it remains more of a research/pharmacogenomic curiosity than an actionable clinical biomarker.
More of a research and pharmacogenomic curiosity than an actionable clinical biomarker at this time.
- General biochemistry/genetics reference literature distinguishing GBA3 (cytosolic beta-glucosidase) from GBA (lysosomal glucocerebrosidase).